drug
Vaxneuvance
Marketedupdated 3mo agoby $MRK Merck & Co., Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying Vaxneuvance
- phase3A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
- phase3Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
- phase3A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
- phase3A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- phase3A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that